Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Biotech stocks hitting 52-week highs on Oct. 1)
- Boston Scientific Corporation BSX
- Eli Lilly And Co LLY
- Masimo Corporation MASI
- Merck & Co., Inc. MRK
- Merit Medical Systems, Inc. MMSI
- Trevena Inc TRVN
- Urovant Sciences Ltd. UROV
Down In The Dumps
(Biotech stocks hitting 52-week lows on Oct. 1)
- Arvinas Inc ARVN
- Avrobio Inc AVRO
- Genprex Inc GNPX
- Gritstone Oncology, Inc. GRTS
- GTx, Inc. GTXI
- Kala Pharmaceuticals Inc KALA
- La Jolla Pharmaceutical Company LJPC
- Magenta Therapeutics Inc MGTA
- OptiNose Inc OPTN
- REALM THERAPEUTICS ADR RLM
- Sonoma Pharmaceuticals Inc SNOA
- Titan Pharmaceuticals, Inc. TTNP
- Vital Therapies Inc VTL
See Also: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates
Stocks In Focus
Endologix Expects Q3 Revenues Above Consensus; Raises Low-End Of FY18 Revenue Guidance
Endologix, Inc. ELGX announced preliminary third-quarter results, expecting revenues in the range of $34.3 million to $34.7 million, ahead of the $31.13 million consensus estimate. Citing the current business trends, the company raised the low-end of its 2018 revenue guidance to $150 million from $145 million, while maintaining the high-end at $155 million.
The stock soared 37.21 percent to $2.36 in after-hours trading.
Novartis Out-Licenses 3 Anti-Infectives
Novartis AG NVS said it licensed three novel anti-infective drug candidates to Boston Pharma. These pipeline assets have the potential to treat antibiotic-resistant Gram-negative infections.
Obseva Reports Additional Positive Data For Nolasiban
Obseva SA OBSV released additional positive Phase 3 data from the IMPLANT 2 trial of its oral, oxytocin receptor antagonist Nolasiban in patients undergoing IVF procedures. The data showed that the candidate significantly increased live birth rate following IVF treatment.
An additional Phase 3 trial is set to begin prior to the end of 2018 and is expected to generate primary endpoint, 10-week ongoing pregnancy data, in about 12 months, allowing for a planned MAA submission in Europe by the end of 2019.
Offerings
Epizyme Inc EPZM priced its underwritten public offering of 8.33 million shares of its common stock at $9 per share, a discount to Tuesday's closing price of $9.71. All the shares are to be sold by the company. The company expects gross proceeds of $75 million from the offering.
The stock shed 7.31 percent to $9 in after-hours trading.
GW Pharmaceuticals PLC- ADR GWPH priced its previously announced offering of 1.90 million ADSs, representing 22.8 million ordinary shares, at a price of $158 per ADS. The company expects to raise gross proceeds of about $300 million from the offering.
Kala Pharma said it commenced an underwritten public offering of 7.50 million shares. Separately, the company said it closed its $110 million credit facility with funds managed by Athyrium Capital Management.
The stock fell 9.48 percent to $8.40 in after-hours trading.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.